WATERTOWN, Mass.—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing therapeutics to help improve the lives of patients with serious eye disorders, has announced the appointment of Isabelle Lefebvre as chief regulatory officer. Lefebvre brings over 30 years of global regulatory affairs experience across all phases of drug development including ophthalmic and ocular conditions. She is succeeding John Weet, Ph.D., who be leaving his role as senior vice president, regulatory, following a transition period.

“Isabelle brings a wealth of regulatory strategy experience from large and midsized-global pharmaceutical companies along with a strong track record of leading successful drug approvals in the ocular space, and we are delighted to welcome her to our executive leadership team,” said Nancy Lurker, CEO of EyePoint Pharmaceuticals.
 
“In particular her ophthalmic and ocular expertise will be highly valuable as we progress our retina focused pipeline to bring our innovative products to patients in the U.S. and around the world. I also want to express my sincere gratitude to Dr. Weet for his many years of service to EyePoint, and for his important impact and leadership in building our regulatory infrastructure and contributing to the many successes of our products and pipeline.”
 
Prior to joining EyePoint, Lefebvre was vice president, head of Regulatory Science at Hengrui USA where she was responsible for overseeing U.S. and E.U. regulatory strategies for clinical programs in various phases of development. Previously, she spent 10 years at Bausch Health Companies Inc. where she held roles of increasing responsibility and led the successful approvals of two ocular drug products, Lotemax gel and Vyzulta.